← Back to Search

Anti-inflammatory agent

AMT-101 for Colitis

Phase 2
Waitlist Available
Research Sponsored by Applied Molecular Transport
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

Eligible Conditions
  • Colitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AMT-101Active Control1 Intervention
AMT-101 Tablet
Group II: PlaceboPlacebo Group1 Intervention
Placebo Tablet

Find a Location

Who is running the clinical trial?

Applied Molecular TransportLead Sponsor
4 Previous Clinical Trials
175 Total Patients Enrolled
2 Trials studying Colitis
103 Patients Enrolled for Colitis
~20 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top